Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Neurofibromatosis Type 1 (NF1) and newly diagnosed pre-malignant and malignant peripheral nerve sheath tumors (MPNST) for whom surgery for resection of tumor is indicated.

  • 0 views
  • 10 Jul, 2022
  • 1 location
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …

adrenaline
primary tumor
solid tumour
teratoma
ipilimumab
  • 6637 views
  • 10 Aug, 2022
  • 752 locations
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs

  • 0 views
  • 15 Mar, 2022
  • 7 locations
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)

The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerate dose of the study drug will be determined. In the Phase II …

metastasis
platelet count
mpnst
solid tumour
KIT
  • 0 views
  • 26 Jan, 2022
  • 4 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant …

metastasis
renal function test
blood transfusion
metarrestin
platelet count
  • 6 views
  • 28 Jul, 2022
  • 2 locations
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

metastatic malignant peripheral nerve sheath tumors (MPNST), endometrial stromal sarcomas (ESS) and leiomyosarcoma (LMS). Participants will continue on study until disease progression or unacceptable side

metastasis
platelet count
mpnst
soft tissue sarcoma
leiomyosarcoma
  • 0 views
  • 18 Apr, 2022
  • 1 location
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

measurable disease
  • 0 views
  • 29 Jul, 2022
  • 4 locations
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

STK11
LKB1
metastatic urothelial carcinoma
cancer chemotherapy
pembrolizumab
  • 34 views
  • 27 Jul, 2022
  • 19 locations
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and …

shortening fraction
left ventricular fractional shortening
platelet count
metastatic disease
gilbert's syndrome
  • 0 views
  • 25 Jul, 2022
  • 1 location
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

stem cell transplantation
trastuzumab
biological therapy
metastatic disease
solid tumour
  • 484 views
  • 13 May, 2022
  • 1 location